Postpartum psychosis

Summary

Postpartum psychosis (MONDO:0018623) is a disease and 4 clinical trials. Top therapeutic interventions include brexanolone. A subtype of psychotic disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: 1-9 / 100 000 (Worldwide) [Orphanet-validated]
• Clinical trials: 4

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	1-9 / 100 000	4	Worldwide	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	postpartum psychosis
Mondo ID	MONDO:0018623
Orphanet	443173
ICD-10-CM	F53, F53.1
SNOMED CT	18260003
UMLS	C0520678
MedGen	636162
GARD	0021853
Is cancer (heuristic)	no

Also known as: puerperal psychosis

Disease family

This is a subtype of psychotic disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › cognitive disorder › psychotic disorder › postpartum psychosis

Related subtypes (7): schizophreniform disorder, alcoholic psychosis, delusional disorder, substance-induced psychosis, schizophrenia, methamphetamine-induced psychosis, schizoaffective disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05314153	EARLY_PHASE1	COMPLETED	Effects Zulresso on Postpartum Psychosis
NCT01172106	Not specified	UNKNOWN	Impact of Family Psychoeducation on Psychosis
NCT02661789	Not specified	COMPLETED	Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression
NCT03615794	Not specified	COMPLETED	A Study of Pregnant and Postpartum Women With and Without Mood Disorders

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BREXANOLONE	4	1